Payment overview · 2025
General Payments
$452.07
23 reported records · 8 companies
Healthcare provider profile · identity verified
Ruben E Brinckhaus, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORTUNA, CA · NPI 1891708806
Verified facts
What the public records show
CMS Open Payments records show Ruben E Brinckhaus, MD received $452.07 in general payments during 2025 across 23 reported records.
Lilly USA, LLC accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.80 | 32.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $129.25 | 28.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.30 | 9.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $35.88 | 7.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.91 | 6.8% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.96 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.49 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.48 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $452.07 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.33 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.24 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.16 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.54 | 3 | 2025 |
Source payment records
|
|||||
| Otezla Normalized: otezla |
Drug | Amgen Inc. | $43.30 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 329 | 66 |
| Gabapentin | Gabapentin | 282 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 197 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 31 |
| Omeprazole | Omeprazole | 139 | 38 |
| Pregabalin | Pregabalin | 136 | 26 |
| Lorazepam | Lorazepam | 131 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 127 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 110 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 27 |
| Metformin Hcl | Metformin Hcl | 101 | 29 |
| Trazodone Hcl | Trazodone Hcl | 100 | 19 |
| Mirtazapine | Mirtazapine | 97 | 19 |
| Eliquis | Apixaban | 96 | 19 |
| Lisinopril | Lisinopril | 96 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 24 |
| Clonazepam | Clonazepam | 88 | 13 |
| Meloxicam | Meloxicam | 87 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 14 |
| Losartan Potassium | Losartan Potassium | 79 | 25 |
| Potassium Chloride | Potassium Chloride | 74 | 20 |
| Carvedilol | Carvedilol | 73 | 21 |
| Hydromorphone Hcl | Hydromorphone Hcl | 73 | suppressed |
| Furosemide | Furosemide | 71 | 25 |
| Simvastatin | Simvastatin | 71 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 25 |
| Ibuprofen | Ibuprofen | 68 | 14 |
| Diazepam | Diazepam | 62 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 15 |
| Alprazolam | Alprazolam | 56 | 12 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Finasteride | Finasteride | 54 | 12 |
| Tramadol Hcl | Tramadol Hcl | 52 | 15 |
| Famotidine | Famotidine | 48 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Methadone Hcl | Methadone Hcl | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 43 | 11 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Fentanyl | Fentanyl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 14 |
| Sertraline Hcl | Sertraline Hcl | 40 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 13 |
| Temazepam | Temazepam | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 11 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 18 |
| Digoxin | Digoxin | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 11 |
| Ozempic | Semaglutide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $452.07 · 23 records | Lilly USA, LLC | CREON, JOURNAVX, MOUNJARO, Otezla, Ozempic, PURIFIED CORTROPHIN GEL, Qelbree, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error